TY - JOUR
T1 - Early manifestations of dementing illness
T2 - Treatment with glycosaminoglycan polysulfate
AU - Ban, Thomas A.
AU - Morey, Leslie C.
AU - Fjetland, Olaf K.
AU - Rengo, Franco
AU - Ferrara, Nicola
AU - Agnetti, Virgilio
AU - D'onofrio, Marina
AU - Facchini, Giulio
AU - Anzivino, Fernando
AU - Perego, Maria Alessandra
AU - Danese, Chiara
AU - Capurso, Antonio
AU - Tommasi, Antonio
AU - Scardigli, Gualtiero
AU - Jans, Giovanni
AU - Parnetti, Lucilla
AU - Senin, Umberto
AU - Bergamasco, Bruno
PY - 1992
Y1 - 1992
N2 - 1. In a multicenter, placebo-controlled, double-blind clinical trial in 156 elderly patients with psychopathologic symptoms, glycosaminoglycan polysulfate was found to be a therapeutlcally effective agent in the treatment of the earliest manifestations of a dementing process. 2. Treatment with glycosaminoglycan polysulfate in the daily dosage of 600 LRU, administered on the basis of a divided dosage schedule for 24 weeks, was significantly superior to an inactive placebo on several several outcome measures including the SCAG Total and factor scores (i.e., Cognitive Dysfunction, Withdrawal, Agitation/Irritability and Depression), the NOHLIS Total and Fatiguability factor scores, the MMSE, the HAM-D Total and Vegetative Symptoms factor score and the CGI Severity of Illness and Global Improvement. 3. The drug was well tolerated; vital signs and laboratory measures did not show clinically significant changes within the experimental period.
AB - 1. In a multicenter, placebo-controlled, double-blind clinical trial in 156 elderly patients with psychopathologic symptoms, glycosaminoglycan polysulfate was found to be a therapeutlcally effective agent in the treatment of the earliest manifestations of a dementing process. 2. Treatment with glycosaminoglycan polysulfate in the daily dosage of 600 LRU, administered on the basis of a divided dosage schedule for 24 weeks, was significantly superior to an inactive placebo on several several outcome measures including the SCAG Total and factor scores (i.e., Cognitive Dysfunction, Withdrawal, Agitation/Irritability and Depression), the NOHLIS Total and Fatiguability factor scores, the MMSE, the HAM-D Total and Vegetative Symptoms factor score and the CGI Severity of Illness and Global Improvement. 3. The drug was well tolerated; vital signs and laboratory measures did not show clinically significant changes within the experimental period.
KW - dementia
KW - elderly
KW - glycosaminoglycan polysulfate
KW - psychopathologic symptoms
KW - treatment
UR - http://www.scopus.com/inward/record.url?scp=0026650884&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026650884&partnerID=8YFLogxK
U2 - 10.1016/0278-5846(92)90023-8
DO - 10.1016/0278-5846(92)90023-8
M3 - Article
C2 - 1379739
AN - SCOPUS:0026650884
VL - 16
SP - 661
EP - 676
JO - Progress in Neuro-Psychopharmacology and Biological Psychiatry
JF - Progress in Neuro-Psychopharmacology and Biological Psychiatry
SN - 0278-5846
IS - 5
ER -